Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
oncology (119) 119
index medicus (68) 68
colorectal cancer (59) 59
humans (57) 57
colorectal neoplasms - drug therapy (47) 47
bevacizumab (40) 40
female (40) 40
male (40) 40
metastasis (38) 38
aged (36) 36
cancer (36) 36
colorectal neoplasms - pathology (36) 36
chemotherapy (33) 33
middle aged (32) 32
antineoplastic combined chemotherapy protocols - therapeutic use (29) 29
metastatic colorectal cancer (27) 27
colorectal neoplasms - genetics (26) 26
metastases (26) 26
adult (25) 25
cetuximab (24) 24
colorectal carcinoma (23) 23
camptothecin - analogs & derivatives (20) 20
colorectal neoplasms - mortality (20) 20
mutation (20) 20
neoplasm metastasis (20) 20
patients (20) 20
care and treatment (19) 19
irinotecan (19) 19
prognosis (18) 18
treatment outcome (18) 18
oxaliplatin (17) 17
research (17) 17
survival (17) 17
analysis (16) 16
camptothecin - administration & dosage (16) 16
disease-free survival (16) 16
therapy (16) 16
tumors (16) 16
1st-line treatment (15) 15
clinical trials (15) 15
panitumumab (15) 15
braf (13) 13
fluorouracil (13) 13
proto-oncogene proteins b-raf - genetics (13) 13
fluorouracil - administration & dosage (12) 12
hematology, oncology and palliative medicine (12) 12
kaplan-meier estimate (12) 12
kras (12) 12
leucovorin - administration & dosage (12) 12
receptor, epidermal growth factor - antagonists & inhibitors (12) 12
aged, 80 and over (11) 11
drug therapy (11) 11
genetic aspects (11) 11
leucovorin (11) 11
ras proteins - genetics (11) 11
retrospective studies (11) 11
angiogenesis inhibitors - therapeutic use (10) 10
antineoplastic combined chemotherapy protocols - administration & dosage (10) 10
adenocarcinoma - drug therapy (9) 9
angiogenesis (9) 9
antibodies, monoclonal, humanized - administration & dosage (9) 9
antineoplastic combined chemotherapy protocols - adverse effects (9) 9
folfoxiri (9) 9
liver neoplasms - drug therapy (9) 9
liver neoplasms - secondary (9) 9
organoplatinum compounds - administration & dosage (9) 9
proto-oncogene proteins - genetics (9) 9
proto-oncogene proteins p21 (9) 9
resistance (9) 9
antibodies, monoclonal - therapeutic use (8) 8
biomarkers (8) 8
confidence intervals (8) 8
follow-up studies (8) 8
usage (8) 8
5-fluorouracil (7) 7
antibodies, monoclonal - administration & dosage (7) 7
antibodies, monoclonal, humanized (7) 7
bevacizumab - administration & dosage (7) 7
digestive system diseases (7) 7
medical research (7) 7
monoclonal antibodies (7) 7
mutations (7) 7
open-label (7) 7
phase-iii (7) 7
proportional hazards models (7) 7
settore med/06 - oncologia medica (7) 7
single-nucleotide polymorphism (7) 7
survival analysis (7) 7
trial (7) 7
alleles (6) 6
antineoplastic agents - therapeutic use (6) 6
bevacizumab - therapeutic use (6) 6
camptothecin - therapeutic use (6) 6
cancer patients (6) 6
cancer therapies (6) 6
capecitabine (6) 6
cells (6) 6
combination (6) 6
efficacy (6) 6
fluorouracil - therapeutic use (6) 6
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
by Cremolini, Chiara, MD and Loupakis, Fotios, PhD and Antoniotti, Carlotta, MD and Lupi, Cristiana, BSc and Sensi, Elisa, PhD and Lonardi, Sara, MD and Mezi, Silvia, MD and Tomasello, Gianluca, MD and Ronzoni, Monica, MD and Zaniboni, Alberto, MD and Tonini, Giuseppe, Prof and Carlomagno, Chiara, PhD and Allegrini, Giacomo, MD and Chiara, Silvana, MD and D'Amico, Mauro, MD and Granetto, Cristina, MD and Cazzaniga, Marina, MD and Boni, Luca, MD and Fontanini, Gabriella, Prof and Falcone, Alfredo, Prof
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 13, pp. 1306 - 1315
Summary Background In the TRIBE study, FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus bevacizumab significantly improved... 
Hematology, Oncology and Palliative Medicine | TRIAL | CETUXIMAB | SURROGATE | LEUCOVORIN | ONCOLOGY | END-POINT | PROGRESSION-FREE SURVIVAL | RAS MUTATIONS | GUIDELINES | KRAS | FLUOROURACIL | Leucovorin - administration & dosage | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Bevacizumab - therapeutic use | Bevacizumab - adverse effects | Colorectal Neoplasms - genetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Angiogenesis Inhibitors - administration & dosage | Neoplasm Metastasis | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Time Factors | DNA Mutational Analysis | Colorectal Neoplasms - drug therapy | Angiogenesis Inhibitors - therapeutic use | Camptothecin - administration & dosage | Female | Angiogenesis Inhibitors - adverse effects | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Bevacizumab - administration & dosage | Drug Administration Schedule | Kaplan-Meier Estimate | Proportional Hazards Models | Proto-Oncogene Proteins - genetics | Treatment Outcome | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Intention to Treat Analysis | Italy | Aged | Infusions, Intravenous | Mutation | Colorectal Neoplasms - pathology | Antimitotic agents | Cancer patients | Care and treatment | Patient outcomes | Analysis | Colorectal cancer | Leucovorin | Metastasis | Antineoplastic agents | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
by Loupakis, Fotios and Cremolini, Chiara and Masi, Gianluca and Lonardi, Sara and Zagonel, Vittorina and Salvatore, Lisa and Cortesi, Enrico and Tomasello, Gianluca and Ronzoni, Monica and Spadi, Rosella and Zaniboni, Alberto and Tonini, Giuseppe and Buonadonna, Angela and Amoroso, Domenico and Chiara, Silvana and Carlomagno, Chiara and Boni, Luca and Boni, Corrado and Allegrini, Giacomo and Falcone, Alfredo
The New England Journal of Medicine, ISSN 0028-4793, 10/2014, Volume 371, Issue 17, pp. 1609 - 1618
In patients with metastatic colon cancer, fluorouracil, oxaliplatin, and irinotecan plus bevacizumab, as compared with fluorouracil and irinotecan plus... 
1ST-LINE TREATMENT | MEDICINE, GENERAL & INTERNAL | INFUSIONAL FLUOROURACIL | LEUCOVORIN | MANAGEMENT | PHASE-III | GUIDELINES | IRINOTECAN | OXALIPLATIN | CHEMOTHERAPY | FOLFIRI | Follow-Up Studies | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Bevacizumab | Fluorouracil - therapeutic use | Antibodies, Monoclonal, Humanized - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Neoplasm Metastasis - drug therapy | Colorectal Neoplasms - drug therapy | Adult | Female | Leucovorin - therapeutic use | Liver Neoplasms - secondary | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Antibodies, Monoclonal, Humanized - adverse effects | Camptothecin - adverse effects | Camptothecin - therapeutic use | Kaplan-Meier Estimate | Liver Neoplasms - drug therapy | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Colorectal Neoplasms - pathology | Organoplatinum Compounds - therapeutic use | Organoplatinum Compounds - adverse effects | Treatment outcome | Care and treatment | Analysis | Colorectal cancer | Dosage and administration | Leucovorin | Fluorouracil | Colorectal carcinoma | Diarrhea | Metastasis | Survival | Patients | Clinical outcomes | Metastases | Irinotecan | Stomatitis | Chemotherapy | Neurotoxicity | Oxaliplatin | Monoclonal antibodies | Vascular endothelial growth factor | Neutropenia | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer
by Marmorino, Federica and Salvatore, Lisa and Barbara, Cecilia and Allegrini, Giacomo and Antonuzzo, Lorenzo and Masi, Gianluca and Loupakis, Fotios and Borelli, Beatrice and Chiara, Silvana and Banzi, Maria Chiara and Miraglio, Emanuela and Amoroso, Domenico and Dargenio, Francesco and Bonetti, Andrea and Martignetti, Angelo and Paris, Myriam and Tomcikova, Daniela and Boni, Luca and Falcone, Alfredo and Cremolini, Chiara
British Journal of Cancer, ISSN 0007-0920, 01/2017, Volume 116, Issue 3, pp. 318 - 323
Background: Different antiangiogenics are currently indicated in the second-line treatment of metastatic colorectal cancer (mCRC), following a first-line... 
LDH | bevacizumab beyond progression | predictive marker | LEUCOVORIN | PHASE-III | OXALIPLATIN | FLUOROURACIL | COMBINATION | 1ST PROGRESSION | ONCOLOGY | LACTATE-DEHYDROGENASE LEVELS | DOUBLE-BLIND | IRINOTECAN | 1ST-LINE THERAPY | Adenocarcinoma - pathology | Bevacizumab - therapeutic use | Prognosis | Humans | Middle Aged | Male | Treatment Outcome | Adenocarcinoma - drug therapy | Disease Progression | Biomarkers, Tumor - blood | Neoplasm Metastasis | L-Lactate Dehydrogenase - blood | Colorectal Neoplasms - drug therapy | Angiogenesis Inhibitors - therapeutic use | Adult | Female | Aged | Chemotherapy, Adjuvant | Colorectal Neoplasms - pathology | Index Medicus | Translational Therapeutics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text When to use triplet chemotherapy as first-line treatment in metastatic colorectal cancer
by Cremolini, Chiara
Clinical advances in hematology & oncology : H&O, ISSN 1543-0790, 08/2019, Volume 17, Issue 8, pp. 433 - 435
Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: An updated analysis
by Masi, Gianluca and Vasile, Enrico and Loupakis, Fotios and Cupini, Samanta and Fornaro, Lorenzo and Baldi, Giacomo and Salvatore, Lisa and Cremolini, Chiara and Stasi, Irene and Brunetti, Isa and Fabbri, Maria Agnese and Puglisi, Martina and Trenta, Patrizia and Granetto, Cristina and Chiara, Silvana and Fioretto, Luisa and Allegrini, Giacomo and Crin, Lucio and Andreuccetti, Michele and Falcone, Alfredo
Journal of the National Cancer Institute, ISSN 0027-8874, 01/2011, Volume 103, Issue 1, pp. 21 - 30
Background Breast reconstruction after mastectomy for cancer requires accurate evaluation to inform evidence-based participatory decision making, but the... 
1ST-LINE TREATMENT | INFUSIONAL FLUOROURACIL | LEUCOVORIN | ONCOLOGY | BEVACIZUMAB | FOLFOXIRI | PHASE-III | TUMOR RESPONSE | IMPROVED SURVIVAL | IRINOTECAN | OXALIPLATIN | Colorectal Neoplasms - surgery | Leucovorin - administration & dosage | Multivariate Analysis | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Male | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Colorectal Neoplasms - drug therapy | Adult | Camptothecin - administration & dosage | Female | Camptothecin - analogs & derivatives | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Remission Induction | Disease-Free Survival | Sample Size | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Infusions, Intravenous | Colorectal Neoplasms - pathology | Neoplasm Staging | Chemotherapy | Metastasis | Drug therapy | Methods | Colorectal cancer | Cancer | Clinical trials | Monoclonal antibodies | Toxins | Clinical outcomes | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Heterogeneity of acquired resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer
by Pietrantonio, Filippo and Vernieri, Claudio and Siravegna, Giulia and Mennitto, Alessia and Berenato, Rosa and Perrone, Federica and Gloghini, Annunziata and Tamborini, Elena and Lonardi, Sara and Morano, Federica and Picciani, Benedetta and Busico, Adele and Volpi, Chiara Costanza and Martinetti, Antonia and Battaglin, Francesca and Bossi, Ilaria and Pellegrinelli, Alessio and Milione, Massimo and Cremolini, Chiara and Di Bartolomeo, Maria and Bardelli, Alberto and De Braud, Filippo
Clinical Cancer Research, ISSN 1078-0432, 05/2017, Volume 23, Issue 10, pp. 2414 - 2422
Purpose: Even if RAS-BRAF wild-type and HER2/MET-negative metastatic colorectal cancer (mCRC) patients frequently respond to anti-EGFR mAbs, acquired... 
PANITUMUMAB | CETUXIMAB | THERAPY | ONCOLOGY | RAS MUTATIONS | TUMOR | CLONAL EVOLUTION | BRAF | KRAS | BLOCKADE | MET | Receptor, Epidermal Growth Factor - genetics | Receptor, ErbB-2 - genetics | Proto-Oncogene Proteins p21(ras) - genetics | Colorectal Neoplasms - genetics | Humans | Middle Aged | Male | Neoplasm Metastasis | Antibodies, Monoclonal, Humanized - administration & dosage | Colorectal Neoplasms - drug therapy | Adult | Female | Colorectal Neoplasms - blood | Membrane Proteins - genetics | Proto-Oncogene Proteins c-met - genetics | Biomarkers, Tumor - blood | Disease-Free Survival | Drug Resistance, Neoplasm - genetics | GTP Phosphohydrolases - genetics | Proto-Oncogene Proteins B-raf - genetics | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Circulating Tumor DNA - blood | Mutation | Colorectal Neoplasms - pathology | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Biomarkers of primary resistance to trastuzumab in HER2-positive metastatic gastric cancer patients: The AMNESIA case-control study
by Pietrantonio, Filippo and Fuca, Giovanni and Morano, Federica and Gloghini, Annunziata and Corso, Simona and Aprile, Giuseppe and Perrone, Federica and De Vita, Ferdinando and Tamborini, Elena and Tomasello, Gianluca and Gualeni, Ambra Vittoria and Ongaro, Elena and Busico, Adele and Giommoni, Elisa and Volpi, Chiara Costanza and Laterza, Maria Maddalena and Corallo, Salvatore and Prisciandaro, Michele and Antista, Maria and Pellegrinelli, Alessandro and Castagnoli, Lorenzo and Pupa, Serenella M and Pruneri, Giancarlo and de Braud, Filippo and Giordano, Silvia and Cremolini, Chiara and Bartolomeo, Maria Di
Clinical Cancer Research, ISSN 1078-0432, 03/2018, Volume 24, Issue 5, pp. 1082 - 1089
Purpose: Refining the selection of HER2-positive metastatic gastric cancer patient candidates for trastuzumab is a challenge of precision oncology. Preclinical... 
CELL LUNG-CANCER | BREAST-CANCER | EGFR MONOCLONAL-ANTIBODIES | GASTROESOPHAGEAL ADENOCARCINOMA | IMPACT | THERAPY | ONCOLOGY | COLORECTAL-CANCER | PHASE-III | GENOMIC ALTERATIONS | HER2 | Prospective Studies | Trastuzumab - pharmacokinetics | Humans | Middle Aged | Receptor, ErbB-2 - metabolism | Male | Response Evaluation Criteria in Solid Tumors | Stomach Neoplasms - pathology | Case-Control Studies | Patient Selection | Aged, 80 and over | Adult | Female | Receptor, ErbB-2 - antagonists & inhibitors | Trastuzumab - pharmacology | Stomach Neoplasms - genetics | Trastuzumab - therapeutic use | Stomach Neoplasms - drug therapy | Antineoplastic Agents, Immunological - pharmacology | Drug Resistance, Neoplasm - genetics | Antineoplastic Agents, Immunological - therapeutic use | Progression-Free Survival | Survival Analysis | Aged | Biomarkers, Tumor - genetics | Mutation | Precision Medicine - methods | Impact prediction | Metastasis | Stomach cancer | Metastases | c-Met protein | Confidence intervals | Receptors | Alterations | Bioindicators | Amnesia | Protein-tyrosine kinase | Gastric cancer | Predictive control | Tyrosine | Epidermal growth factor receptors | Patients | ErbB-2 protein | 1-Phosphatidylinositol 3-kinase | Signaling | Experimental design | Biomarkers | PTEN protein | Trastuzumab | Tumors | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as initial treatment for metastatic colorectal cancer (TRIBE study): Updated survival results and final molecular subgroups analyses
by Loupakis, F and Cremolini, C and Antoniotti, C and Lonardi, S and Ronzoni, M and Zaniboni, A and Tonini, G and Salvatore, L and Chiara, S and Carlomagno, C and Banzi, C and Negri, F and Marcucci, L and Barone, C and Fontanini, G and Borrelli, N and Giordano, M and Macerola, E and Boni, L and Falcone, A
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 05/2015, Volume 33, Issue 15, pp. 3510 - 3510
ONCOLOGY
Conference Proceeding
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text The landscape of d16HER2 splice variant expression across HER2-positive cancers
by Volpi, Chiara Costanza and Pietrantonio, Filippo and Gloghini, Annunziata and Fucà, Giovanni and Giordano, Silvia and Corso, Simona and Pruneri, Giancarlo and Antista, Maria and Cremolini, Chiara and Fasano, Elena and Saggio, Serena and Faraci, Simona and Di Bartolomeo, Maria and de Braud, Filippo and Di Nicola, Massimo and Tagliabue, Elda and Pupa, Serenella Maria and Castagnoli, Lorenzo
Scientific Reports, ISSN 2045-2322, 12/2019, Volume 9, Issue 1, pp. 3545 - 12
The HER2 splice variant characterized by the deletion of exon 16 and denominated as d16HER2, is associated with HER2-positive breast cancer (BC)... 
BREAST-CANCER | THERAPY | TRASTUZUMAB | EFFICACY | GASTRIC-CANCER | MULTIDISCIPLINARY SCIENCES | AMERICAN-PATHOLOGISTS | OPEN-LABEL | HER2 | PERTUZUMAB | GUIDELINE | Alternative splicing | Clonal deletion | Colorectal carcinoma | Xenografts | Breast cancer | mRNA | Hybridization | Exosomes | Gastric cancer | ErbB-2 protein | Trastuzumab | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial
by Masi, Gianluca, Dr and Loupakis, Fotios, MD and Salvatore, Lisa, MD and Fornaro, Lorenzo, MD and Cremolini, Chiara, MD and Cupini, Samanta, MD and Ciarlo, Andrea, MD and Del Monte, Francesca, PhD and Cortesi, Enrico, MD and Amoroso, Domenico, MD and Granetto, Cristina, MD and Fontanini, Gabriella, Prof and Sensi, Elisa, MD and Lupi, Cristiana, MD and Andreuccetti, Michele, CTA and Falcone, Alfredo, MD
Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 9, pp. 845 - 852
Summary Background The FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) regimen has been shown to be better than FOLFIRI (fluorouracil,... 
Hematology, Oncology and Palliative Medicine | LIVER METASTASES | INFUSIONAL FLUOROURACIL | LEUCOVORIN | K-RAS | PLUS IRINOTECAN | ONCOLOGY | CLINICAL-TRIALS | TUMOR RESPONSE | ORAL FLUOROPYRIMIDINES | BICC-C | CHEMOTHERAPY | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Bevacizumab | Antibodies, Monoclonal, Humanized | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Colorectal Neoplasms - drug therapy | Adult | Camptothecin - administration & dosage | Female | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Camptothecin - adverse effects | Kaplan-Meier Estimate | Adenocarcinoma - drug therapy | Disease-Free Survival | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Organoplatinum Compounds - adverse effects | Adenocarcinoma - mortality | Chemotherapy | Oncology, Experimental | Colorectal cancer | Clinical trials | Metastasis | Research | Angiogenesis inhibitors | Drug therapy | Cancer | Medical research | Analysis | Medicine, Experimental | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients
by Siravegna, Giulia and Mussolin, Benedetta and Buscarino, Michela and Corti, Giorgio and Cassingena, Andrea and Crisafulli, Giovanni and Ponzetti, Agostino and Cremolini, Chiara and Amatu, Alessio and Lauricella, Calogero and Lamba, Simona and Hobor, Sebastijan and Avallone, Antonio and Valtorta, Emanuele and Rospo, Giuseppe and Medico, Enzo and Motta, Valentina and Antoniotti, Carlotta and Tatangelo, Fabiana and Bellosillo, Beatriz and Veronese, Silvio and Budillon, Alfredo and Montagut, Clara and Racca, Patrizia and Marsoni, Silvia and Falcone, Alfredo and Corcoran, Ryan B and Di Nicolantonio, Federica and Loupakis, Fotios and Siena, Salvatore and Sartore-Bianchi, Andrea and Bardelli, Alberto
Nature Medicine, ISSN 1078-8956, 07/2015, Volume 21, Issue 7, pp. 795 - 801
Colorectal cancers (CRCs) evolve by a reiterative process of genetic diversification and clonal evolution. The molecular profile of CRC is routinely assessed... 
MEDICINE, RESEARCH & EXPERIMENTAL | BIOCHEMISTRY & MOLECULAR BIOLOGY | ACQUIRED-RESISTANCE | SENSITIVE DETECTION | DRUG-RESISTANCE | NUCLEIC-ACIDS | CELL BIOLOGY | KRAS MUTATIONS | HETEROGENEITY | DROPLET DIGITAL PCR | MELANOMA | THERAPY | FREE TUMOR DNA | Antibodies - therapeutic use | Receptor, Epidermal Growth Factor - genetics | Receptor, Epidermal Growth Factor - immunology | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Colorectal Neoplasms - blood | Antibodies, Neoplasm - blood | Colorectal Neoplasms - genetics | Humans | Proto-Oncogene Proteins - genetics | Antineoplastic Agents - therapeutic use | Mutation - genetics | Antibodies - pharmacology | Drug Resistance, Neoplasm - genetics | DNA, Neoplasm - blood | Colorectal Neoplasms - drug therapy | Alleles | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Antineoplastic Agents - pharmacology | Clone Cells | Colorectal Neoplasms - pathology | Clonal Evolution | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text BRAF V600E Mutation as a Negative Prognostic Determinant in Resected Colorectal Liver Metastases
by Moretto, Roberto and Cremolini, Chiara and Falcone, Alfredo
JAMA surgery, ISSN 2168-6254, 12/2018, Volume 153, Issue 12, pp. 1162 - 1163
Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text TRIBE-2: A phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group
by Cremolini, Chiara and Marmorino, Federica and Loupakis, Fotios and Masi, Gianluca and Antoniotti, Carlotta and Salvatore, Lisa and Schirripa, Marta and Boni, Luca and Zagonel, Vittorina and Lonardi, Sara and Aprile, Giuseppe and Tamburini, Emiliano and Ricci, Vincenzo and Ronzoni, Monica and Pietrantonio, Filippo and Valsuani, Chiara and Tomasello, Gianluca and Passardi, Alessandro and Allegrini, Giacomo and Di Donato, Samantha and Santini, Daniele and Falcone, Alfredo and Investigators Grp Oncologico and all the investigators of the Gruppo Oncologico del Nord Ovest and on behalf of all the investigators of the Gruppo Oncologico del Nord Ovest
BMC Cancer, ISSN 1471-2407, 06/2017, Volume 17, Issue 1, pp. 408 - 408
Background: Chemotherapy plus bevacizumab is a standard first-line treatment for unresectable metastatic colorectal cancer patients. Different chemotherapy... 
Folfoxiri | Clinical trial | Strategy | Colorectal cancer | Bevacizumab | 1ST-LINE CHEMOTHERAPY | INTERMITTENT | OXALIPLATIN | COMBINATION | NON-INFERIORITY | THERAPY | ONCOLOGY | PLUS BEVACIZUMAB | CONTINUATION | PROGRESSION | Chemotherapy, Combination | Care and treatment | Patient outcomes | Clinical trials | Diagnosis | Research | Comparative analysis | Health aspects | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Lactate dehydrogenase (LDH) levels to predict benefit from the continuation of bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): Subgroup analysis of the randomized BEBYP study
by Marmorino, F and Cremolini, C and Loupakis, F and Barbara, C and Dargenio, F and Miraglio, E and Masi, G and Salvatore, L and Marcucci, L and Antonuzzo, L and Chiara, S and Banzi, C and Schirripa, M and Amoroso, D and Bonetti, A and Martignetti, A and Paris, M and Boni, L and Tomcikova, D and Falcone, A
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 05/2016, Volume 34, Issue 15, pp. e15127 - e15127
ONCOLOGY
Conference Proceeding
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text Primary tumor location as a prognostic factor in metastatic colorectal cancer
by Loupakis, Fotios and Loupakis, Fotios and Yang, Dongyun and Yau, Linda and Feng, Shibao and Cremolini, Chiara and Zhang, Wu and Maus, Martin K. H and Antoniotti, Carlotta and Langer, Christiane and Scherer, Stefan J and Müller, Thomas and Hurwitz, Herbert I and Saltz, Leonard and Falcone, Alfredo and Lenz, Heinz-Josef
Journal of the National Cancer Institute, ISSN 0027-8874, 03/2015, Volume 107, Issue 3, p. 1
Background: We sought to clarify the prognostic impact of primary tumor location in metastatic colorectal cancer (mCRC). Methods: We evaluated the association... 
COLON-CANCER | SURVIVAL | EVOLUTION | PATTERN | ONCOLOGY | BEVACIZUMAB | 1ST-LINE THERAPY | EPIDEMIOLOGY | Colorectal Neoplasms - mortality | Predictive Value of Tests | Prognosis | Prospective Studies | Humans | Middle Aged | Kaplan-Meier Estimate | Proportional Hazards Models | Logistic Models | Male | Bevacizumab | Randomized Controlled Trials as Topic | Disease-Free Survival | Clinical Trials, Phase III as Topic | Antibodies, Monoclonal, Humanized - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Colorectal Neoplasms - drug therapy | Female | Aged | Colorectal Neoplasms - pathology | Neoplasm Staging | Odds Ratio | Chemotherapy | Metastasis | Analysis | Colorectal cancer | Cancer | Care and treatment | Survival analysis | Medical prognosis | Clinical trials | Tumors | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
16. Full Text Bevacizumab as maintenance therapy in mCRC: Interpreting results of the MOMA trial
by Marmorino, Federica and Falcone, Alfredo and Cremolini, Chiara
Oncotarget, ISSN 1949-2553, 04/2019, Volume 10, Issue 29, pp. 2791 - 2792
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights